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tients with Type 1a glycogen storaga b s t r a c t
Hepatic glucose production and relative Krebs cycle fluxes (indexed to a citrate synthase flux of 1.0)
were evaluated with [U-13C]glycerol tracer in 5 fed healthy controls and 5 Type 1a glycogen storage
disease (GSD1a) patients. Plasma glucose, hepatic glucose-6-phosphate (G6P) and glutamine 13C-
isotopomers were analyzed by 13C NMR via blood sampling and chemical biopsy. In healthy subjects,
35714% of plasma glucose originated from hepatic G6P while GSD1a patients had no detectable G6P
contribution. Compared to controls, GSD1a patients had an increased fraction of acetyl-CoA from
pyruvate (0.570.2 vs. 0.370.1, po0.01), and increased pyruvate recycling fluxes (14.473.8 vs. 8.772.8,
po0.05). Despite negligible gluconeogenic flux, net anaplerotic outflow was not significantly different
from controls (2.270.8 vs. 1.370.5). The enrichment of lactate with 13C-isotopomers derived from the
Krebs cycle suggests that lactate was the main anaplerotic product in GSD1a patients.
& 2009 Elsevier Inc. All rights reserved.1. Introduction
In Type 1a glycogen storage disease (GSD1a), hepatic glucose-
6-phosphatase (G6P-ase) is inactive resulting in major changes of
systemic glucose metabolism both upstream and downstream of
hepatic glucose-6-phosphate (G6P) (Bandsma et al., 2002a,
2002b). The capacity to maintain plasma glucose levels during
fasting is impaired because endogenous glucose cannot be
synthesized from either glycogen or gluconeogenic precursors
since G6P is a common intermediate for both pathways. Normally,
when glucose release via the absorption of dietary carbohydrate is
insufficient to meet systemic demand, the balance is supplied by
the hydrolysis of hepatic G6P to glucose by glucose-6-phospha-
tase. In GSD1a patients, the lack of G6P-ase activity means that
hepatic carbon fluxes that would normally be destined for glucose
production are necessarily redirected to other pathways. Although
G6P can be disposed as glycogen, the hydrolysis of glycogen to
glucose—which is largely dependent on G6P-ase—is also blocked.
This results in the characteristic overabundance of hepatic
glycogen, which cannot be relieved by fasting glycogenolysis.
Under these conditions, the capacity for converting G6P toll rights reserved.
, Hepatic anaplerotic outflow
e disease. Metab. Eng. (200glycogen on a daily basis is likely very small and can only account
for a very minor portion of G6P flux that is normally destined for
endogenous glucose production.1
Under both fasting and fed conditions, a significant fraction of
hepatic G6P and plasma glucose is derived from gluconeogenic
carbons originating from the anaplerotic pathways of the Krebs
cycle, with pyruvate being the principal precursor. Gluconeogen-
esis is considered to account for the majority of anaplerotic
outflow from the Krebs cycle (Rognstad and Katz, 1977; Magnus-
son et al., 1991; Katz et al., 1993; Beylot et al., 1995).
Gluconeogenic flux is largely sustained by the conversion of
pyruvate to phosphoenolpyruvate (PEP) via pyruvate carboxylase
(PC) and phosphoenolpyruvate carboxykinase (PEP-ck). Pyruvate
may also be oxidized to acetyl-CoA via pyruvate dehydrogenase
(PDH) hence substrate competition between PC and PDH can
potentially regulate the rate of pyruvate conversion to G6P (Beylot
et al., 1995; Large and Beylot, 1999). Another potential regulatory
mechanism is the recycling of PEP to pyruvate via pyruvate kinase
that completes a futile cycle (pyruvate-oxaloacetate-PEP-
pyruvate) (Rognstad and Katz, 1977; Magnusson et al., 1991; Jones
et al., 1997; Diraison et al., 1998; She et al., 2003; Jin et al., 2005).
Operation of this cycle may attenuate gluconeogenic flux in two1 Fasting hepatic glucose production is 3mg/kg/min or 5.4 g/h for a 30kg
child (Kien et al., 1995). Gluconeogenesis contributes 1.5mg/kg/min or 2.7 g/h.
Assuming a liver mass of 800 g and a glycogen concentration of 0.46M (Roser et al.,
1996), the total hepatic glycogen mass is 66 g, hence 1h of glucose production is
equivalent to about 10% of the total hepatic glycogen mass.
fluxes are redirected from gluconeogenesis to lactate synthesis
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Fig. 1. Hepatic metabolite sampling for 13C-enrichment following the incorpora-
tion of 13C from [U-13C]glycerol into hepatic intermediary metabolism in the
presence of acetaminophen and phenylbutyric acid. Hepatic UDP-glucose (UDPG)
and glutamine are sampled as urinary acetaminophen glucuronide and phenyla-
cetylglutamine (PAGN), respectively. Glucose and lactate are sampled directly from
plasma. Also shown are the pyruvate, Krebs cycle and gluconeogenic metabolic
pathway components whose relative fluxes are derived from the 13C-isotopomer
distribution of PAGN: 1 ¼ citrate synthase flux, 2 ¼ pyruvate dehydrogenase flux,
3 ¼ acyl-CoA oxidation flux, 4 ¼ pyruvate carboxylase flux, 5 ¼ phosphoenol-
pyruvate carboxykinase flux, 6 ¼ pyruvate kinase flux and 7 ¼ net PEP flux to G6P.
Fig. 2. Tracer and meal administration protocol.
J.G. Jones et al. / Metabolic Engineering ] (]]]]) ]]]–]]]2ways: first by redirecting anaplerotic flux from all sources
(including anaplerotic substrates that enter the Krebs cycle as 4
and 5-carbon skeletons, such as aspartate, glutamate and
glutamine) to pyruvate, and second, by consuming ATP that could
otherwise fuel gluconeogenesis. In GSD1a patients, gluconeogen-
esis is negligible; hence the carbon outflow that would normally
be destined for glucose synthesis must either be attenuated by the
mechanisms described or redirected into alternative disposal
pathways.
To study hepatic G6P-ase and Krebs cycle fluxes, we designed a
stable-isotope tracer study that is summarized in Fig. 1. The
procedure is non-invasive and can be accommodated into the
cornstarch feeding regime of GSD1a patients. [U-13C]Glycerol was
used as means of delivering 13C into the hepatic triose-P pool. This
substrate has some key advantages in that it is palatable and can
be mixed with the cornstarch meal and is also efficiently extracted
and metabolized by the liver. [U-13C]Glycerol was accompanied by
two xenobiotic agents, acetaminophen and phenylbutyric acid,
designed to safely sample key hepatic metabolites as conjugates
that are cleared into urine. Acetaminophen is metabolized to
acetaminophen glucuronide with the glucuronide moiety derived
from UDP-glucose (Hellerstein et al., 1986). Phenylbutyric acid can
undergo b-oxidation to phenylacetyl-CoA, which then combines
with hepatic glutamine to form phenylacetylglutamine (PAGN)
(Comte et al., 2002). Hepatic glutamine is derived in part from the
Krebs cycle intermediate a-ketoglutarate, hence the 13C-enrich-
ment distribution of acetyl-CoA and the Krebs cycle can be
inferred from PAGN (Yang et al., 1993; Jones et al., 1998, 2001;
Diraison et al., 1999). The 13C-enrichment and isotopomer
distributions of PAGN and acetaminophen glucuronide, as well
as plasma glucose and lactate, can be quantified by 13C NMR
following simple extraction and purification procedures (Jones et
al., 1998, 2001). The relative activities of anaplerotic and oxidative
Krebs cycle fluxes and the pyruvate futile cycle can then be
derived from the 13C-enrichment or isotopomer distribution of
PAGN (Diraison et al., 1998; Jones et al., 1998, 2001).Please cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflo
in patients with Type 1a glycogen storage disease. Metab. Eng. (2002. Methods
2.1. Human studies
Five patients with Type 1a glycogen storage disease (3M, 2F;
1476yr; 3579kg) and 5 controls (1M, 4F; 2074yr; 53713kg)
were studied following informed consent. For those subjects
under 18 years old, informed consent was obtained from the
parents. All GSD1a patients were on cornstarch therapy, receiving
1g/kg of cornstarch every 3h. The tracer study was incorporated
into a set of four cornstarch meals spanning 9h (Fig. 2). With the
second cornstarch meal, subjects ingested 500mg acetaminophen
and with the third meal, subjects ingested 200mg phenylbutyric
acid and 1 g [U-13C]glycerol. Immediately before the final
cornstarch meal, 15ml venous blood was drawn and immediately
centrifuged. Plasma was removed and frozen until further
processing. Urines were collected over 3-h periods as shown.
2.2. Processing of urinary metabolites and plasma glucose
Urine samples were adjusted to pH 7.0 and incubated over-
night with 10,000U of urease per sample. A trace of sodium azide
was also added to inhibit possible infection from airborne
microorganisms. The samples were then depleted of protein by
addition of perchloric acid, followed by neutralization, centrifuga-
tion and lyophilization. Upon reconstitution in 2–3ml water, the
pH was adjusted to 8.0, the sample loaded on to a 16-ml Dowex-
18-acetate column and washed with 25ml of water. PAGN and
acetaminophen glucuronide were eluted with 35ml of 10M acetic
acid. This fraction was evaporated and re-suspended in 0.5–1.0ml
water. The pH was adjusted to 7.0 with NaOH, and the samples
were centrifuged in Eppendorf tubes. A total of 0.5ml of the
supernatant was introduced into a 5-mm NMR tube and 0.1ml of
deuterated acetonitrile was added to provide a deuterium field-
frequency lock signal. Plasmawas depleted of protein, neutralized,
centrifuged and lyophilized. The lyophilized extract was sus-
pended in 0.6 ml deuterated water and centrifuged, and the
supernatant transferred into a 5 mm NMR tube for NMR analysis.
2.3. NMR spectroscopy
Proton-decoupled 13C NMR spectra were acquired at 11.75 T
with a Varian Unity 500 system equipped with a 5-mm broadband
‘‘switchable’’ probe with z-gradient (Varian, Palo Alto, CA). Spectra
were obtained at 50 1C. An acquisition time of 2 s and inter-pulse
delay of 1 s were used and the number of acquisitions ranged from
5000 to 25,000. The relative areas of 13C NMR multiplets were
quantified using the curve-fitting routine supplied with the NUTS
PC-based NMR spectral analysis program (Acorn NMR Inc.,w fluxes are redirected from gluconeogenesis to lactate synthesis
9), doi:10.1016/j.ymben.2009.01.003
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system and probe with pre-saturation of the water signal.
2.4. Metabolic flux analyses
2.4.1. Main assumptions
The metabolic flux measurements are based on the following
general assumptions: (1) isotopic steady-state of the hepatic
intermediary metabolite pools (glycolytic/gluconeogenic sugar
phosphate intermediates and Krebs cycle metabolites); (2) liver is
the principal site of [U-13C]glycerol metabolism (Landau et al.,
1996); and (3) oxidative pentose phosphate pathway flux relative
to those of gluconeogenesis or glycolysis flux is assumed to be
negligible (Magnusson et al., 1988).
2.4.2. Fractional contribution of G6P hydrolysis to plasma glucose
The singlet signal of each resonance was assumed to represent
the natural abundance 13C-enrichment of 1.11%. 13C-Excess
enrichment in carbons 6 of glucose was estimated from the total
area of the 13C–13C spin–spin coupled doublet relative to the
central singlet multiplied by 1.11%. Both a and b carbon 6 signals
were analyzed. 13C-Excess enrichment in carbon 6 of hepatic G6P
was estimated from the glucuronide carbon 6 resonance, which
was also resolved into singlet and 13C–13C spin–spin coupled
doublet components. Assuming that all glucose excess 13C-
enrichment of carbon 6 was derived from carbon 6 of hepatic
G6P, the fraction of plasma glucose derived from G6P was
estimated as follows:Excess G6P carbon 6 enrichment ð%Þ
¼ ðglucuronide carbon 6 doublet=carbon 6 singletÞ1:11
Excess plasma glucose carbon 6 enrichment
¼ ðplasma glucose carbon 6 doublet=carbon6 singletÞ1:11:
Percent of plasma glucose derived from G6P
¼ 100 ðglucose excess carbon 6 enrichment=G6P excess carbon 6 enrichmentÞ:2.4.3. PAGN 13C-isotopomer analysis and hepatic Krebs cycle fluxes
13C-isotopomers and positional enrichments of the glutamine
moiety of PAGN were quantified from the 13C NMR multiplet
signals. The singlet signal of each resonance was assumed to
represent the natural abundance 13C-enrichment of 1.11%. 13C-
Excess enrichment in each of the five glutamine carbons was
estimated from the total area of the 13C–13C spin–spin coupled
multiplets relative to the central singlet multiplied by 1.11%.
Glutamine 13C-isotopomer ratios were quantified from resolved
13C–13C spin–spin coupled multiplet components of each reso-
nance. 13C-Excess enrichment and 13C-isotopomer ratios were
applied to tcaCALC (Malloy et al., 1990), a program developed by
Dr Mark Jeffrey of the Advanced Imaging Research Center at the
University of Texas Southwestern Medical Center at Dallas which
is available for download at http://www.utsouthwestern.edu/
utsw/home/research/AIRC. There was total of 10 input variables:
glutamine carbon 1–4 excess enrichment levels and the following
six glutamine 13C-multiplet ratios; carbon 1 doublet/singlet,
carbon 2 1,2,3-13C3-quartet/singlet, carbon 2 1,2-
13C2-doublet/
singlet, carbon 2 2,3-13C2-doublet/singlet, carbon 3 doublet/
singlet and carbon 4 doublet/singlet. The 13C NMR isotopomer
data were fitted to a standard model of the hepatic Krebs cycle
shown in Fig. 1. 13C Input into the Krebs cycle is assumed to be
[U-13C]pyruvate derived from the glycolytic metabolism of
[U-13C]glycerol. Flux parameters are relative to that of citratePlease cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflow
in patients with Type 1a glycogen storage disease. Metab. Eng. (200synthase, arbitrarily set to 1.0. The model had 5 degrees of
freedom and the uncertainty of each flux parameter was
estimated with 100 Monte-Carlo simulations. Fittings were
performed systematically starting with a basic Krebs cycle model
featuring the simplest set of metabolic conditions (i.e. acetyl-CoA
enrichment from labeled pyruvate with no anaplerosis) then
adding more parameters until the experimental and calculated
13C-multiplet data showed the best fit (Fonseca et al., 2005). The
model accounted for the input of natural abundance 13C as well as
enrichment from [U-13C]pyruvate.3. Results
3.1. Glucose synthesis from hepatic G6P
In the 13C NMR spectrum, 13C-enrichment of glucuronide or
glucose from [U-13C]glycerol is resolved from the background
natural abundance 13C signal as a result of 13C–13C spin–spin
coupling. As illustrated in Fig. 3, the glucuronide carbon 6
resonance has a singlet signal reflecting the natural abundance
13C and a doublet arising from 13C–13C coupling between carbon 6
and the neighboring carbon 5. The doublet signal reflects the
excess 13C-enrichment from metabolism of [U-13C]glycerol since
its conversion to G6P via [U-13C]triose phosphates results in the
formation of multiply-labeled 13C-isotopomers, principally
[1,2,3-13C3]and [4,5,6-
13C3]G6P. The [4,5,6-
13C3]G6P isotopomer
contributes to the doublet component of the carbon 6 resonanceof glucuronide. The carbon 6a and b resonances of plasma glucose
also have doublet components reflecting the conversion of
[4,5,6-13C3]G6P to [4,5,6-
13C3]glucose. Since
13C-enriched glucose
can only be derived from 13C-enriched G6P, the excess enrich-
ments of plasma glucose relative to that of glucuronide directly
reflects the fraction of plasma glucose derived from hepatic G6P.
In control subjects, the 13C-signals of both urinary glucuronide
and plasma glucose were enriched with 13C indicating hepatic
metabolism of [U-13C]glycerol to glucose, as shown in Table 1. In
healthy subjects, the fraction of plasma glucose derived from
hepatic G6P-ase had a wide inter-individual range 20–50%,
possibly reflecting differences in the absorption of unlabeled
glucose coupled with variable suppression of hepatic glucose
production during the meal. In comparison, GSD1a patients had a
significantly reduced level of glucuronide 13C-enrichment and no
detectable plasma glucose 13C-enrichment. The absence of excess
plasma glucose 13C-enrichment confirms that no plasma glucose
was derived from hepatic G6P in any of the five patients. The
reduced levels of glucuronide enrichment suggest that flux from
G6P to UDP-glucose was lower in these patients compared to
healthy controls. The possibility that reduced glucuronide enrich-
ment could reflect reduced uptake and metabolism of [U-13C]gly-
cerol is discounted by the appearance of 13C-enrichment in other
sites such as the hepatic Krebs cycle and plasma lactate. Analysis
of the carbon 5 glucuronide signal revealed that in addition to thefluxes are redirected from gluconeogenesis to lactate synthesis
9), doi:10.1016/j.ymben.2009.01.003
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amounts of [5,6-13C2]G6P present (data not shown). The latter
isotopomer most probably arises from the metabolism of
[U-13C]glycerol to [U-13C]pyruvate, followed by conversion to
G6P via gluconeogenesis. As a result of label exchange and
randomization at the level of oxaloacetate, the [U-13C]pyruvate
moiety is converted to a 50/50 mixture of [U-13C]PEP and
[2,3-13C2]PEP isotopomers. Gluconeogenesis of [2,3-
13C2]PEP
results in the formation of [5,6-13C2]G6P. The activity of the futile
pyruvate cycle increases the amount of [2,3-13C2]PEP at the
expense of the [U-13C]PEP isotopomer. The presence of
[5,6-13C2]G6P confirms that a portion of the [U-
13C]glycerol tracer
was metabolized via hepatic Krebs cycle and is consistent with the
observation of PAGN 13C-isotopomers (derived from a-ketogluta-
rate).Table 1
Urinary glucuronide and plasma glucose carbon 6 13C NMR signal ratios (C6D, C6S), e
glucose derived from hepatic G6P derived from glucose and glucuronide excess enrich
Glucuronide C6D/
(C6D+C6S)
Glucose C6D/
(C6D+C6S)
Controls
1 0.64 0.42
2 0.49 0.32
3 0.65 0.25
4 0.63 0.43
5 0.60 0.26
Mean7S.D. 0.6070.06 0.3470.09
GSD1a
1 0.00 0.00
2 0.17 0.00
3 0.07 0.00
4 0.21 0.00
5 0.34 0.00
Mean7S.D. 0.1670.13 0.0070.00
Fig. 3. 13C NMR signals of acetaminophen b-glucuronide carbon 6 and plasma
glucose a, b carbon 6 from a healthy control and from a GSD1a patient. Where
noted, each NMR signal is resolved into a singlet (S) and doublet (D). The singlet
signal represents the 1.11% natural abundance 13C while the doublet signal
represents the contribution of [4,5,6-13C3] and [5,6-
13C2]hexose isotopomers,
shown schematically on the left. The resonance marked ‘‘x’’ is an unassigned 13C
NMR signal not related to glucose.
Please cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflo
in patients with Type 1a glycogen storage disease. Metab. Eng. (2003.2. Hepatic Krebs cycle 13C-enrichment and meta0bolic fluxes from
PAGN analysis
Urinary PAGN was produced by all subjects in quantities
ranging from 150 to 400mmol. In contrast to a recent study of
phenylbutyrate metabolism that documented the urinary produc-
tion of both PAGN and phenylbutyrylglutamine (Comte et al.,
2002), only PAGN was detected in our samples as determined by
1H NMR analysis of both crude and purified urine fractions. The
phenylbutyrate dose used in our study was an order of magnitude
smaller than that described in the study of Comte et al. and may
explain its more efficient conversion to PAGN. The 13C NMR
signals of PAGN recovered from both controls and GSD1a patients
revealed 13C–13C spin coupled multiplets in the five carbons of the
glutamine moiety. Multiplets from carbons 2, 3 and 4 of the
glutamine moiety were selected for quantification of 13C-iso-
topomers because of their higher signal-to-noise ratios under the
NMR acquisition conditions (short repetition time and proton
decoupling with nuclear Overhauser effect (nOe)) in comparison
to the carbon 1 and 5 carboxyl resonances. The carboxyl signals
were much weaker due to the absence of nOe and also because of
extensive saturation resulting from their long spin-lattice relaxa-
tion times. Moreover, the isotopomer information from the 13C-
multiplet signals of carbons 1 and 5 is redundant under our study
conditions (i.e. the [4,5-13C2]glutamine isotopomer that forms the
doublet signal of carbon 5 is also represented by the doublet
signal of carbon 4 while isotopomers that contribute to the carbon
1 doublet; [1,2-13C2]glutamine and [1,2,3-
13C3]glutamine, are also
represented in the carbon 2 multiplet). Fig. 4 shows the 13C
resonances of carbons 2, 3 and 4 from a healthy subject and
GSD1a patient 1, who had no detectable 13C-enrichment of
glucose or glucuronide. The presence of significant levels of
glutamine carbon 4 enrichment (see Table 2), invalidates the
estimation of anaplerotic, pyruvate recycling and gluconeogenic
fluxes directly from the carbon 2 multiplet ratios (Jones et al.,
1997). Nevertheless, inspection of the multiplets and 13C-
isotopomer ratios provides some qualitative information on the
hepatic flux profiles. Carbons 4 and 5 of PAGN originate from
carbons 2 and 1 of acetyl-CoA, hence the presence of
[4,5-13C2]glutamine indicates the production of [1,2-
13C2]acetyl-
CoA from [U-13C]pyruvate via pyruvate dehydrogenase. For all
subjects, the D23 doublet signal of carbon 2 was substantially
higher than the quartet (Q) contribution, reflecting a large excess
of [2,3-13C2]glutamine relative to [1,2,3-
13C3]glutamine and
indicative of extensive pyruvate recycling (Jones et al., 1997,xcess glucuronide and glucose carbon 6 enrichments, and the fraction of plasma
ments.
Glucuronide C6 excess
enrichment
Glucose C6 excess
enrichment
Percent of glucose
derived from G6P
1.97 0.80 41
1.07 0.52 49
2.06 0.37 18
1.89 0.84 44
1.67 0.39 23
1.7370.40 0.5870.22 35714
0.00 0.00 0
0.22 0.00 0
0.08 0.00 0
0.30 0.00 0
0.57 0.00 0
0.2370.22 0.0070.00 070
w fluxes are redirected from gluconeogenesis to lactate synthesis
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Fig. 5 and the flux outputs reflect the qualitative metabolic profile
gleaned from inspection of the PAGN 13C-multiplets. In control
subjects, about one-third of acetyl-CoA utilized by the Krebs cycle
was derived from pyruvate oxidation via pyruvate dehydrogenase
(PDH). The fractional contribution of PDH flux to the acetyl-CoA
pool was significantly higher in the GSD1a subjects, accounting
for over one-half of acetyl-CoA generation. This difference in PDH
flux contribution to acetyl-CoA is evident by a greater intensity of
the carbon 4 doublet signal relative to that of carbon 3 for GSD1a
patients, as illustrated by the spectra in Fig. 4. This reflects a
higher abundance of [4,5-13C2]glutamine relative to the other
13C-
isotopomers in GSD1a subjects compared to controls (see Table 2).
In the metabolic model of the Krebs cycle, [U-13C]pyruvate
oxidation to acetyl-CoA is well defined by the enrichment level
of [4,5-13C2]glutamine and this isotopomer signal could be
measured with high precision in the 13C NMR spectrum. For each
subject, this translated into narrow confidence intervals (typicallyTable 2
Hepatic glutamine 13C-isotopomer abundances and excess 13C-enrichments derive
phenylacetylglutamine.
Healthy controls
1 2 3 4 5 Mea
13C-isotopomer abundances (%)
[1,2-13C2]PAGN 0.06 0.07 0.08 0.15 0.17 0.10
[2,3-13C2]PAGN 0.57 0.56 0.72 0.81 0.86 0.70
[1,2,3-13C3]PAGN 0.12 0.14 0.16 0.21 0.20 0.17
[4,5-13C2]PAGN 0.22 0.23 0.09 0.41 0.65 0.32
13C-Excess enrichment (%)
Carbon 2 0.74 0.78 0.95 1.15 1.22 0.97
Carbon 3 0.65 0.68 0.76 0.84 0.90 0.77
Carbon 4 0.22 0.23 0.09 0.41 0.65 0.32
Fig. 4. 13C NMR multiplet signals of phenylacetylglutamine carbons 2, 3 and 4
from a healthy control and from GSD1a patient 1 that had no 13C-enrichment of
either glucuronide or glucose. Each multiplet is resolved into isotopomer
components as follows: carbon 2; S ¼ natural abundance singlet signal,
D12 ¼ doublet reflecting 13C in both positions 1 and 2, D23 ¼ doublet reflecting
13C in both positions 2 and 3, Q ¼ quartet reflecting 13C in positions 1, 2 and 3,
Carbon 3; S ¼ natural abundance singlet signal, D ¼ doublet reflecting 13C in both
positions 2 and 3 regardless of position 1, carbon 4; S ¼ natural abundance singlet
signal, D45 ¼ doublet reflecting 13C in both positions 4 and 5. Hepatic glutamine
13C-isotopomers represented by the 13C NMR signals are shown schematically on
the top left-hand side.
Please cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflow
in patients with Type 1a glycogen storage disease. Metab. Eng. (20010–30% of the flux estimate, see Table 3) as estimated by Monte-
Carlo simulations.
In healthy subjects, flux through pyruvate carboxylase, PEP-
carboxykinase and pyruvate kinase, constituting the pyruvate
cycling pathway, was an order of magnitude higher than the
oxidative Krebs cycle flux indicating high pyruvate cycling activity
(Jones et al., 1997, 1998, 2001). Net anaplerotic outflow was about
1.5 times that of oxidative Krebs flux and amounted to10% of the
pyruvate cycling activity. In GSD1a subjects, pyruvate cycling
fluxes were even higher than those of controls. Despite the
blockage of gluconeogenic outflow, net anaplerotic fluxes also
tended to be higher in GSD1a patients, amounting to about twice
that of oxidative Krebs cycle flux. These results need to be
interpreted with caution since the anaplerotic and pyruvate
kinase flux estimates of each subject were associated with larger
confidence intervals (50–150% of the flux values, see Table 3)
compared with those obtained for pyruvate oxidation flux. There
are two reasons for this: first, the 13C-glutamine isotopomers that
define anaplerotic and pyruvate cycling fluxes, notably
[1,2-13C2]glutamine and [1,2,3-
13C3]glutamine, were present in
low abundance as seen by their respective D12 and Q signals in
the carbon 2 resonance of Fig. 4. Thus, the quantification of these
signals was less certain compared to those from other 13C-d from the analysis of the carbon 2, 3 and 4 13C NMR signals of urinary
GSD1a patients
n7S.D. 1 2 3 4 5 Mean7S.D.
70.05 0.04 0.07 0.04 0.09 0.07 0.0670.02
70.13 0.35 0.53 0.48 0.87 0.43 0.5370.20
70.04 0.09 0.12 0.12 0.27 0.12 0.1470.07
70.21 0.31 0.45 0.18 0.70 0.29 0.3970.20
70.21 0.49 0.75 0.66 1.22 0.66 0.7670.27
70.11 0.41 0.61 0.64 0.90 0.52 0.6270.18
70.21 0.31 0.45 0.18 0.70 0.29 0.3970.20
Fig. 5. Relative flux estimates for selected metabolite transformations for healthy
subjects (white) and GSD1a patients (black). Data represent the mean values for
each group. The error bar on each column represents the standard deviation of the
mean. ***po0.01 relative to healthy controls; **po0.025 relative to healthy
controls, *po0.05 relative to healthy controls.
fluxes are redirected from gluconeogenesis to lactate synthesis
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Table 3
Estimates of pyruvate dehydrogenase (PDH), pyruvate carboxylase (YPC) and pyruvate kinase (PK) fluxes, relative to a citrate synthase flux of 1.0 obtained by tcaCALC
analysis of the PAGN 13C NMR spectra.
Flux estimates Healthy controls
Control 1 Control 2 Control 3 Control 4 Control 5
PDH (7S.D.) [5–95% C.I.] 0.28 (0.01) [0.27–0.29] 0.28 (0.02) [0.25–0.30] 0.29 (0.02) [0.25–0.34] 0.10 (0.01) [0.09–0.11] 0.30 (0.09) [0.14–0.45]
YPC (7S.D.) [5–95% C.I.] 13.48 (0.84) [12.48–15.11] 12.84 (4.28) [10.11–24.20] 7.06 (1.03) [5.92–9.03] 9.89 (0.72) [8.83–11.19] 5.89 (4.42) [2.74–14.33]
PK (7S.D.) [5–95% C.I.] 11.80 (0.58) [11.12–12.87] 10.83 (2.79) [8.81–18.28] 6.10 (0.88) [5.10–8.17] 8.89 (0.62) [7.99–9.95] 5.15 (2.94) [1.48–10.60]
GSD1a Patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
PDH (7S.D.) [5–95% C.I.] 0.66 (0.03) [0.62–0.71] 0.63 (0.05) [0.55–0.72] 0.29 (0.03) [0.24–0.32] 0.63 (0.05) [0.56–0.73] 0.53 (0.06) [0.43–0.64]
YPC (7S.D.) [5–95% C.I.] 14.21 (1.57) [12.40–17.17] 21.92 (N.D.) [14.99–49.96] 12.87 (N.D.) [8.04–28.38] 18.04 (3.80) [14.27–26.10] 15.88 (N.D.) [11.41–28.95]
PK (7S.D.) [5–95% C.I.] 12.76 (1.24) [11.18–15.34] 19.87 (N.D.) [13.30–42.25] 9.55 (9.23) [7.06–19.51] 15.35 (2.84) [12.53–21.33] 14.36 (N.D.) [10.45–26.07]
Also shown are the associated uncertainties obtained by Monte-Carlo simulation. Uncertainties are reported as standard deviation (S.D.) and 5–95% confidence intervals
(C.I.). In some cases, the Monte-Carlo simulation did not return standard deviation values, and these are noted as not determined (N.D.).
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tcaSIM2 to determine the unit change in anaplerotic and pyruvate
recycling fluxes in response to changing the 13C NMR multiplet
ratios revealed that these relative flux estimates are quite
sensitive to small errors in the D12 and Q multiplet contributions
(data not shown).Fig. 6. 13C NMR signals of plasma glucose and lactate from a GSD1a patient. The
lactate carbon 2 signal and its 13C–13C spin–spin coupled multiplets are shown in
expanded form. The carbon 2 multiplet is resolved into isotopomer components as
follows: carbon 2; S ¼ natural abundance singlet signal, D12 ¼ doublet reflecting
13C in both positions 1 and 2, D23 ¼ doublet reflecting 13C in both positions 2 and
3, Q ¼ quartet reflecting 13C in positions 1, 2 and 3 reflecting 13C in both positions 4
and 5. The identity and abundance of lactate 13C-isotopomers represented by the
13C NMR signals of carbon 2 are shown schematically to the left.3.3. Enrichment of plasma and urinary lactate from [U-13C]glycerol
Plasma lactate was enriched with 13C in both healthy and
GSD1a subjects. Significant levels of urinary lactate were detected
by 1H and 13C NMR in three of the five GSD1a patients while none
was detected in healthy subjects. For the three GSD1a patients
that had urinary lactate, the carbon 2 and 3 13C-signals had similar
13C NMR multiplet structures to those of plasma lactate indicating
that urinary lactate was also enriched from [U-13C]glycerol. In
healthy subjects, plasma lactate levels relative to glucose were
0.3070.06, as assessed by the natural abundance 13C-lactate/13C-
glucose signal ratios. In GSD1a patients, the plasma lactate to
glucose ratio was 1.6371.33 reflecting a much higher availability
of lactate relative to glucose as an oxidizable substrate for
peripheral tissues. In healthy subjects, 13C-enrichment levels of
plasma lactate carbon 3 were estimated to be 0.670.3%. These
values correspond to the carbon 6 enrichment levels of plasma
glucose3 and are consistent with Cori cycle activity where plasma
lactate is derived from peripheral tissue glycolysis of endogenous
glucose. In GSD1a patients, plasma and urinary lactate were also
enriched with 13C. Plasma lactate carbon 3 enrichment levels were
0.470.2%, slightly lower than that of control subjects. However,
given the high plasma lactate concentrations and the additional
lactate recovered in urine in GSD1a patients, this level of 13C-
enrichment represents a much larger mass conversion of
[U-13C]glycerol to 13C-lactate compared to that of healthy control
subjects. Since plasma glucose was not enriched with 13C in the
GSD1a patients, the 13C-lactate enrichment could not have been
derived from plasma glucose via the Cori cycle but instead must
have been directly derived from the liver. The plasma lactate
isotopomer distribution, as shown in Fig. 6, revealed significant
amounts of [1,2-13C2] and [2,3-
13C2]lactate isotopomers, which are
derived from passage of the [U-13C]glycerol moiety through the2 tcaSIM is also available from http://www.utsouthwestern.edu/utsw/home/
research/AIRC.
3 Glucose enriched with 13C in carbon 6 (and/or carbon 1) will generate lactate
enriched in carbon 3.
Please cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflo
in patients with Type 1a glycogen storage disease. Metab. Eng. (200hepatic Krebs cycle and pyruvate recycling pathways. This
indicates that a substantial portion of the 13C-enriched lactate
was derived via the anaplerotic fluxes of the Krebs cycle, rather
than by direct glycolysis of [U-13C]glycerol (which would only
generate the [1,2,3-13C3]lactate isotopomer).4. Discussion
In this study, the complete block of carbon flow from hepatic
intermediary metabolites to glucose in GSD1a patients was
confirmed using a gluconeogenic tracer. In previous metabolic
tracer studies of GSD1 children, [U-13C]glucose was given by
nasogastric infusion and plasma glucose was analyzed for 13C-
isotopomers (Kalderon et al., 1988, 1989). Under normal condi-
tions, metabolism of infused [U-13C]glucose generates a popula-
tion of partially labeled 13C-glucose molecules through the
recycling of 13C-tracer via glycolysis, hepatic gluconeogenesis
and glucose production (Tayek and Katz, 1996). In GSD1a patients,w fluxes are redirected from gluconeogenesis to lactate synthesis
9), doi:10.1016/j.ymben.2009.01.003
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of hepatic glucose production from G6P. In these studies, plasma
lactate was enriched with 13C and in addition to [U-13C]lactate
derived by simple glycolysis, lactate 13C-isotopomers containing
one or two 13C atoms were also detected. These latter isotopomers
are generated during passage of the [U-13C]pyruvate moiety
through the anaplerotic pathways of the hepatic Krebs cycle.
While these studies provide evidence for blocked hepatic glucose
production and the involvement of the hepatic Krebs cycle in the
synthesis of 13C-lactate from [U-13C]glucose, the 13C-isotopomer
information from plasma glucose and lactate is not sufficient for
describing specific hepatic Krebs cycle fluxes.
In current models of human hepatic intermediary metabolism,
gluconeogenesis is assumed to be the main pathway for
anaplerotic carbon outflow from the hepatic Krebs cycle (Mag-
nusson et al., 1991; Esenmo et al., 1992; Landau et al., 1993; Large
et al., 1997; Diraison et al., 1998; Jones et al., 2001; Burgess et al.,
2003). This assumption is based on the fact that under most
conditions, gluconeogenic flux is much higher than other
potential net outflow fluxes from the hepatic Krebs cycle, such
as amino acid or citrate synthesis. Although several independent
studies have focused on quantifying human gluconeogenic and
oxidative hepatic Krebs cycle fluxes from the labeling distribution
of hepatic glutamine from a gluconeogenic tracer, estimates of
human gluconeogenic outflow relative to oxidative Krebs cycle
activity (i.e. flux through citrate synthase) remain highly un-
certain, possibly because of systematic methodological biases in
the determination of hepatic Krebs cycle fluxes with different
tracers and analytical techniques. Based on the incorporation of
[3-14C]lactate tracer into carbons 1–5 of PAGN, Magnusson et al.
(1991) estimated that gluconeogenic fluxes were 2–3 times that of
citrate synthase flux. These relative flux ratios were similar
between 60-h fasted subjects and overnight-fasted subjects given
a glucose load. In a stable-isotope study using [3-13C]lactate and
analysis of positional 13C-enrichment in PAGN by gas chromato-
graphy-mass spectrometry, gluconeogenic fluxes were estimated
to be 0.5 times those of citrate synthase flux in overnight-fasted
healthy subjects (Diraison et al., 1998). Jones et al. (1998, 2001)
reported gluconeogenic flux values that were approximately equal
to citrate synthase flux in overnight-fasted subjects and 1.4
times citrate synthase flux in 24-h fasted subjects using
[U-13C]propionate as a gluconeogenic tracer and 13C NMR analysis
of PAGN ().
Estimates of pyruvate recycling fluxes based on phenylacetyl-
glutamine labeling from [3-13C] or [3-14C]lactate tracers, are
typically smaller than those derived from this study or in previous
studies using [U-13C]propionate (Jones et al., 1998, 2001).
Pyruvate recycling fluxes of 4 times citrate synthase flux were
reported in 60-h fasted healthy subjects infused with [3-14C]lac-
tate (Magnusson et al., 1991) while for overnight-fasted subjects
infused with [3-13C]lactate, pyruvate recycling flux was estimated
to be 2 times citrate synthase flux (Diraison et al., 1998). In
common with the 13C-isotopomer methodology presented here,
estimates of pyruvate cycling fluxes from [3-13C]- or [3-14C]lactate
are also subject to high uncertainty because they require
quantification of 13C-enrichment or 14C-specific activity in carbon
5 relative to carbons 2 and 3 of phenylacetylglutamine. Under
most conditions, carbon 5 labeling from these tracers is very low
relative to the other positions and small errors in the measure-
ment of carbon 5 labeling propagate large errors in pyruvate
recycling flux estimates.
The metabolic model assumes metabolic and isotopic steady-
state conditions. To the extent that the 13C-enrichment levels of
triose phosphate and pyruvate were varying over time as the 13C-
glycerol tracer was taken up by the liver and then consumed, a
constant precursor 13C-enrichment level was not maintained inPlease cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflow
in patients with Type 1a glycogen storage disease. Metab. Eng. (200our study. For both control and GSD1a subjects, the sampling
period represented the peak 13C-enrichment levels of glucuronide
and phenylacetylglutamine; i.e. 13C-enrichment levels for these
metabolites were less for urine samples collected before or after
this interval (data not shown). Under metabolic steady-state
conditions the Krebs cycle flux parameters are relatively insensi-
tive to slow changes in 13C-precursor enrichment (Jones et al.,
1998) hence these values are not expected to be significantly
influenced by washing-in and out of the 13C-label. We surmise
that the 3-hourly cornflour ingestion regime maintained a
relatively constant source of absorbed carbohydrate and hepatic
metabolic state, but we acknowledge that other settings such as
an insulin/glucose clamp protocol could provide more precise
metabolic and endocrine control.
Hepatocyte intermediary metabolism is characterized by high
activities of anaplerotic enzymes such as pyruvate carboxylase,
the capacity to utilize a wide range of anaplerotic substrates, and
an abundance of these substrates in the portal vein flow. Our
results with GSD1a patients suggest that a restriction in
gluconeogenic flux imposed from the top down results in a
significant redistribution of carbon fluxes at the level of the
hepatic Krebs cycle. These include an increased recruitment of
acetyl-CoA from pyruvate relative to fatty acid oxidation and
increased pyruvate recycling fluxes. These alterations are accom-
panied by predictable changes in the 13C-isotopomer distribution
of hepatic glutamine. In contrast, a change in the destination of
anaplerotic outflow has no effect on the glutamine 13C-isotopo-
mer distribution and is therefore undefined by glutamine 13C-
isotopomer analysis. Thus, while relative anaplerotic fluxes in
GSD1a patients were similar to those of healthy controls, the
principal destination of anaplerotic carbons in GSD1a patients
was lactate instead of G6P. As a result, gluconeogenic flux was
decoupled from net anaplerotic outflow. In healthy subjects, the
extent to which anaplerotic efflux is diverted from gluconeogen-
esis to lactate production is difficult to resolve by the analysis of
lactate 13C-enrichment from 13C-tracers of the hepatic Krebs cycle.
This is because plasma lactate can become enriched with 13C via
the Cori cycle (i.e. via gluconeogenesis, hepatic glucose production
and peripheral tissue glycolysis) as well as by direct anaplerotic
outflow from the hepatic Krebs cycle.
The utilization of acetyl-CoA by lipogenesis provides another
means for the non-oxidative disposal of carbon from the hepatic
Krebs cycle pool. While de novo lipogenesis fluxes are relatively
small in comparison to Krebs cycle and gluconeogenic fluxes in
healthy subjects, in the few studies performed on GSD1a subjects,
de novo lipogenesis rates of up to 40 times that of healthy controls
were reported (Bandsma et al., 2002a, 2002b). If the removal of
acetyl-CoA for lipogenesis is compensated by an increase in
acetyl-CoA production from pyruvate, oxidative Krebs cycle fluxes
will not be changed. Therefore, in the absence of an independent
measurement of lipogenesis or pyruvate oxidation, it is not
possible to quantify the lipogenic recruitment of acetyl-CoA from
the analysis of glutamine 13C-isotopomers. Finally, there is the
possibility that while relative anaplerotic fluxes were similar
between healthy and GDS1a patients, absolute anaplerotic fluxes
might differ if there was a systematic difference in absolute
hepatic Krebs cycle fluxes between the two groups. To resolve this
would require an independent measure of oxidative hepatic Krebs
cycle activity, such as hepatic oxygen consumption or urea
production.
In summary, our studies demonstrate that in GSD1a patients,
Krebs cycle fluxes are redirected to dispose carbon that would
normally be used for glucose synthesis. The redirection of
anaplerotic flux from gluconeogenesis to lactate production may
be an important part of this adaptation. This mechanism could
also play a role in the regulation of gluconeogenesis in healthyfluxes are redirected from gluconeogenesis to lactate synthesis
9), doi:10.1016/j.ymben.2009.01.003
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outflow implies that under certain conditions, absolute hepatic
Krebs cycle fluxes may need to be evaluated independently of
absolute gluconeogenic fluxes.Acknowledgment
This work was supported by a grant from the Portuguese
Foundation of Science and Technology (POCTI/QUI/55603/2004).
References
Bandsma, R.H.J., Smit, G.P.A., Kuipers, F., 2002a. Disturbed lipid metabolism in
glycogen storage disease type 1. Eur. J. Pediatr. 161, S65–S69.
Bandsma, R.H.J., Rake, J.P., Visser, G., Neese, R.A., Hellerstein, M.K., van
Duyvenvoorde, W., Princen, H.M.G., Stellaard, F., Smit, G.P.A., Kuipers, F.,
2002b. Increased lipogenesis and resistance of lipoproteins to oxidative
modification in two patients with glycogen storage disease type 1a. J. Pediatr.
140, 256–260.
Beylot, M., Soloviev, M.V., David, F., Landau, B.R., Brunengraber, H., 1995. Tracing
hepatic gluconeogenesis relative to citric acid cycle activity in vitro and in vivo.
Comparisons in the use of [3-13C]lactate, [2-13C]acetate, and alpha-keto
[3-13C]isocaproate. J. Biol. Chem. 270, 1509–1514.
Burgess, S.C., Weis, B., Jones, J.G., Smith, E., Merritt, M.E., Margolis, D., Sherry, A.D.,
Malloy, C.R., 2003. Noninvasive evaluation of liver metabolism by 2H and 13C
NMR isotopomer analysis of human urine. Anal. Biochem. 312, 228–234.
Comte, B., Kasumov, T., Pierce, B.A., Puchowicz, M.A., Scott, M.E., Dahms, W., Kerr,
D., Nissim, I., Brunengraber, H., 2002. Identification of phenylbutyrylglutamine,
a new metabolite of phenylbutyrate metabolism in humans. J. Mass Spectrom.
37, 581–590.
Diraison, F., Large, V., Brunengraber, H., Beylot, M., 1998. Non-invasive tracing of
liver intermediary metabolism in normal subjects and in moderately
hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis
and hepatic fatty acid oxidation in NIDDM. Diabetologia 41, 212–220.
Diraison, F., Large, V., Maugeais, C., Krempf, M., Beylot, M., 1999. Noninvasive
tracing of human liver metabolism: comparison of phenylacetate and apoB-
100 to sample glutamine. Am. J. Physiol. 277, E529–E536.
Esenmo, E., Chandramouli, V., Schumann, W.C., Kumaran, K., Wahren, J., Landau,
B.R., 1992. Use of 14CO2 in estimating rates of hepatic gluconeogenesis. Am. J.
Physiol. 263, E36–E41.
Fonseca, C.P., Jones, J.G., Carvalho, R.A., Jeffrey, F.M.H., Montezinho, L.P., Geraldes,
C., Castro, M., 2005. Tricarboxylic acid cycle inhibition by Li+ in the human
neuroblastoma SH-SY5Y cell line: a 13C NMR isotopomer analysis. Neurochem.
Int. 47, 385–393.
Hellerstein, M.K., Greenblatt, D.J., Munro, H.N., 1986. Glycoconjugates as
noninvasive probes of intrahepatic metabolism-pathways of glucose entry
into compartmentalized Hepatic UDP-glucose pools during glycogen accumu-
lation. Proc. Natl. Acad. Sci. USA 83, 7044–7048.
Jin, E.S., Burgess, S.C., Merritt, M.E., Sherry, A.D., Malloy, C.R., 2005. Differing
mechanisms of hepatic glucose overproduction in triiodothyronine-treated
rats vs. Zucker diabetic fatty rats by NMR analysis of plasma glucose. Am. J.
Physiol. 288, E654–E662.Please cite this article as: Jones, J.G., et al., Hepatic anaplerotic outflo
in patients with Type 1a glycogen storage disease. Metab. Eng. (200Jones, J.G., Solomon, M.A., Sherry, A.D., Jeffrey, F.M., Malloy, C.R., 1998. 13C NMR
measurements of human gluconeogenic fluxes after ingestion of [U-13C]pro-
pionate, phenylacetate, and acetaminophen. Am. J. Physiol. 275, E843–E852.
Jones, J.G., Naidoo, R., Sherry, A.D., Jeffrey, F.M.H., Cottam, G.L., Malloy, C.R., 1997.
Measurement of gluconeogenesis and pyruvate recycling in the rat liver: a
simple analysis of glucose and glutamate isotopomers during metabolism of
[1,2,3-13C3]propionate. FEBS Lett. 412, 131–137.
Jones, J.G., Solomon, M.A., Cole, S.M., Sherry, A.D., Malloy, C.R., 2001. An integrated
2H and 13C NMR study of gluconeogenesis and TCA cycle flux in humans. Am. J.
Physiol. 281, E848–E851.
Kalderon, B., Lapidot, A., Korman, S.H., Gutman, A., 1988. Glucose recycling and
production in children with Glycogen Storage Disease Type-I, studied by gas-
chromatography mass-spectrometry and [U-13C]glucose. Biomed. Environ.
Mass Spectrom. 16, 305–308.
Kalderon, B., Korman, S.H., Gutman, A., Lapidot, A., 1989. Glucose recycling and
production in Glycogenosis Type-I and Type-Iii-stable isotope technique study.
Am. J. Physiol. 257, E346–E353.
Katz, J., Wals, P., Lee, W.N., 1993. Isotopomer studies of gluconeogenesis and the
Krebs cycle with 13C-labeled lactate. J. Biol. Chem. 268, 25509–25521.
Kien, C.L., Horswill, C.A., Zipf, W.B., McCoy, K.S., Odorisio, T., 1995. Elevated hepatic
glucose production in children with Cystic Fibrosis. Pediatr. Res. 37, 600–605.
Landau, B.R., Schumann, W.C., Chandramouli, V., Magnusson, I., Kumaran, K.,
Wahren, J., 1993. 14C-labeled propionate metabolism in vivo and estimates of
hepatic gluconeogenesis relative to Krebs cycle flux. Am. J. Physiol. 265,
E636–E647.
Landau, B.R., Wahren, J., Previs, S.F., Ekberg, K., Chandramouli, V., Brunengraber, H.,
1996. Glycerol production and utilization in humans: sites and quantitation.
Am. J. Physiol. 271, E1110–E1117.
Large, V., Beylot, M., 1999. Modifications of citric acid cycle activity and
gluconeogenesis in streptozotocin-induced diabetes and effects of metformin.
Diabetes 48, 1251–1257.
Large, V., Brunengraber, H., Odeon, M., Beylot, M., 1997. Use of labeling pattern of
liver glutamate to calculate rates of citric acid cycle and gluconeogenesis. Am.
J. Physiol. 272, E51–E58.
Magnusson, I., Chandramouli, V., Schumann, W.C., Kumaran, K., Wahren, J., Landau,
B.R., 1988. Pentose pathway in human liver. Proc. Natl. Acad. Sci. USA 85,
4682–4685.
Magnusson, I., Schumann, W.C., Bartsch, G.E., Chandramouli, V., Kumaran, K.,
Wahren, J., Landau, B.R., 1991. Noninvasive tracing of Krebs cycle metabolism in
liver. J. Biol. Chem. 266, 6975–6984.
Malloy, C.R., Sherry, A.D., Jeffrey, F.M.H., 1990. Analysis of tricarboxylic acid cycle of
the heart using 13C isotope isomers. Am. J. Physiol. 259, H987–H995.
Rognstad, R., Katz, J., 1977. Role of pyruvate kinase in the regulation of
gluconeogenesis from L-lactate. J. Biol. Chem. 252, 1831–1833.
Roser, W., Beckmann, N., Wiesmann, U., Seelig, J., 1996. Absolute quantification of
the hepatic glycogen content in a patient with glycogen storage disease by 13C
magnetic resonance spectroscopy. Magn. Reson. Imaging 14, 1217–1220.
She, P.X., Burgess, S.C., Shiota, M., Flakoll, P., Donahue, E.P., Malloy, C.R., Sherry, A.D.,
Magnuson, M.A., 2003. Mechanisms by which liver-specific PEPCK knockout
mice preserve euglycemia during starvation. Diabetes 52, 1649–1654.
Tayek, J.A., Katz, J., 1996. Glucose production, recycling, and gluconeogenesis in
normals and diabetics: a mass isotopomer [U-13C]glucose study. Am. J. Physiol.
270, E709–E717.
Yang, D., Beylot, M., Agarwal, K.C., Soloviev, M.V., Brunengraber, H., 1993. Assay of
the human liver citric acid cycle probe phenylacetylglutamine and of
phenylacetate in plasma by gas chromatography-mass spectrometry. Anal.
Biochem. 212, 277–282.w fluxes are redirected from gluconeogenesis to lactate synthesis
9), doi:10.1016/j.ymben.2009.01.003
